Adenoviridae, Adeno-like Virus, Or Parvoviridae (e.g., Adenovirus, Canine Parvovirus, Mink Enteritis Virus, Hemorrhagic Enteritis Virus, Feline Panleukopenia Virus, Egg Drop Syndrome Virus, Etc.) Patents (Class 424/233.1)
  • Patent number: 10517938
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: December 31, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: JerĂ´me H. H. V. Custers, Jort Vellinga, Marija Vujadinovic, Esmerelda Van Der Helm
  • Patent number: 10501757
    Abstract: A recombinant vector comprises simian adenovirus 43, 45, 46, 47, 48, 49 or 50 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus 43, 45, 46, 47, 48, 49 or 50 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: December 10, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
  • Patent number: 10415056
    Abstract: In one aspect, the present invention provides an intron-modified cap expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 17, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
  • Patent number: 9974737
    Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: May 22, 2018
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventor: Janik Adriaansen
  • Patent number: 9803219
    Abstract: Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: October 31, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Nazim El-Andaloussi, Antonio Marchini, Jean Rommelaere, Barbara Leuchs, Max Endele
  • Patent number: 9707257
    Abstract: Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: July 18, 2017
    Assignee: The University of Notre Dame
    Inventor: Malcolm James Fraser, Jr.
  • Patent number: 9617561
    Abstract: Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: April 11, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
  • Patent number: 9534233
    Abstract: The present invention is related to a nucleic acid construct comprising an expression unit for the expression of E1B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1B, and a 3?UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1B, wherein the 3?UTR comprises 30 or less than 30 Exonic Enhancer Elements (ESEs), preferably 20 or less than 20 Exonic Enhancer Elements (ESEs), and wherein the 3? UTR is a non-viral 3? UTR.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: January 3, 2017
    Inventor: Stefan Kochanek
  • Patent number: 9382551
    Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 5, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson
  • Patent number: 9359618
    Abstract: A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 7, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson, Luk H. Vandenberghe
  • Patent number: 9333253
    Abstract: A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: May 10, 2016
    Assignees: University of Saskatchewan, University of Guelph
    Inventors: Susantha Gomis, Suresh Kumar Tikoo, Davor Ojkic
  • Patent number: 9220768
    Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: December 29, 2015
    Assignee: Novartis AG
    Inventor: Jens-Peter Gregersen
  • Patent number: 9163260
    Abstract: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 20, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Weidong Xiao
  • Publication number: 20150140102
    Abstract: The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method.
    Type: Application
    Filed: July 9, 2013
    Publication date: May 21, 2015
    Inventors: Kevin O'Connell, Sandhya Buchanan
  • Patent number: 9034836
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: May 19, 2015
    Assignee: Genzyme Corporation
    Inventors: James Dodge, Lamya Shihabuddin, Catherine O'riordan
  • Patent number: 9034344
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: May 19, 2015
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Patent number: 9017696
    Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: April 28, 2015
    Assignee: Isis Innovation Limited
    Inventors: Simon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
  • Patent number: 9011820
    Abstract: A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: April 21, 2015
    Assignee: Saint Louis University
    Inventors: Karoly Toth, William S. M. Wold
  • Patent number: 8999946
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: April 7, 2015
    Assignee: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • Publication number: 20150086579
    Abstract: The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 26, 2015
    Inventors: Timothy P. MAYALL, Jeff ALEXANDER
  • Publication number: 20150086590
    Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
    Type: Application
    Filed: February 19, 2013
    Publication date: March 26, 2015
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryuichi Sakamoto, Masashi Sakaguchi
  • Publication number: 20150056251
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody that binds to nicotine or a nicotine analog, or an antigen-binding fragment thereof. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 26, 2015
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson
  • Publication number: 20150050307
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 19, 2015
    Inventors: Christopher James Nicolai, Semih U. Tareen
  • Patent number: 8956606
    Abstract: A malignant tumor cell suppressor protein (a) or (b): (a) a protein comprising an amino acid sequence represented by SEQ ID No. 1; or (b) a protein comprising an amino acid sequence represented by SEQ ID No. 1, wherein one or more amino acid are deleted, substituted or added in the amino acid sequence set forth in SEQ ID No. 1.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 17, 2015
    Inventors: Toshiwo Andoh, Tetsuo Sugahara, Yoshihide Hayashizaki, Yasushi Okazaki
  • Publication number: 20150044258
    Abstract: An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.
    Type: Application
    Filed: December 12, 2012
    Publication date: February 12, 2015
    Inventors: Rainer Ludwig Knaus, Katy Rebecca Newton
  • Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Publication number: 20150017121
    Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
    Type: Application
    Filed: October 10, 2012
    Publication date: January 15, 2015
    Applicant: UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Johannes Vom Berg
  • Patent number: 8932607
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • Patent number: 8926987
    Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: January 6, 2015
    Assignees: The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di Sanita
    Inventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
  • Patent number: 8920813
    Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 30, 2014
    Assignee: GenVec, Inc.
    Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
  • Patent number: 8916176
    Abstract: Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substitution at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 23, 2014
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Nathalie Salome, Christiane Dinsart, Nadine Michel, Jean Rommelaere
  • Patent number: 8906387
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 9, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark Kay, Dirk Grimm
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Publication number: 20140348876
    Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 27, 2014
    Applicant: Arecor Limited
    Inventors: Jan JEZEK, Angela Buckler
  • Patent number: 8889641
    Abstract: The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: November 18, 2014
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Aravind Asokan, Richard Jude Samulski
  • Publication number: 20140322268
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 30, 2014
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. REED, Darrick CARTER
  • Patent number: 8865182
    Abstract: The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 21, 2014
    Assignee: Paxvax, Inc.
    Inventors: Timothy P. Mayall, Jeff Alexander
  • Patent number: 8852607
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 7, 2014
    Assignee: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • Patent number: 8852577
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 7, 2014
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • Patent number: 8846031
    Abstract: Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 30, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
  • Patent number: 8834863
    Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: September 16, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson
  • Patent number: 8808684
    Abstract: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: August 19, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John Chiorini, Michael Schmidt, Melodie L. Weller
  • Publication number: 20140193457
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Inventors: Carla Christina Schrier, Simon ILG
  • Patent number: 8765146
    Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: July 1, 2014
    Assignees: GenVec, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the Navy
    Inventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louise Doolan, Daniel John Carucci
  • Publication number: 20140170187
    Abstract: The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.
    Type: Application
    Filed: July 25, 2012
    Publication date: June 19, 2014
    Inventors: Ethan Settembre, Sumana Chandramouli
  • Patent number: 8734809
    Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: May 27, 2014
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Terence Flotte, Jun Xie
  • Patent number: 8734808
    Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 27, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Publication number: 20140141043
    Abstract: Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 22, 2014
    Applicant: AUBURN UNIVERSITY
    Inventors: Haroldo Enrique Toro Guzman, Qingzhong Yu
  • Publication number: 20140127263
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: OmniGen Research, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Patent number: 8709778
    Abstract: This invention provides methods for adenoviral vector synthesis. The present invention further provides methods for binding adenovirus terminal protein obtained from virus to linear DNA. The present invention further provides a recombinant adenovirus from which the adenovirus terminal protein can be purified with an inverted terminal repeat DNA sequence.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: April 29, 2014
    Inventor: Xavier Danthinne